|
Market Closed -
London S.E.
23:35:17 16/10/2026 HKT
|
5-day change | 1st Jan Change | ||
| 82.50 GBX | 0.00% |
|
+13.79% | +2.48% |
| 10-15 | Arecor Therapeutics Obtains Patents in Europe, US, India, for Rapid-acting Insulin | MT |
| 10-15 | Arecor Therapeutics Plc Strengthens Patent Protection For Its Proprietary AT278 Product | CI |
| Market Cap | 37.37M 49.86M 44.32M 41.08M 70.52M 4.73B 71.66M 494M 194M 2.47B 187M 183M 7.87B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 31.81M 42.43M 37.72M 34.96M 60.02M 4.03B 60.98M 420M 165M 2.1B 159M 156M 6.7B | EV / Sales 2026 * |
106x | EV / Sales 2027 * | 181x |
| Free-Float |
55.19% | Yield 2026 * |
-
| Yield 2027 * | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| AREC | Delayed | |
Deutsche Boerse AG
| 6UI | Delayed | |
|
Börse Stuttgart
| 6UI | Delayed |
Last Transcript: Arecor Therapeutics plc
| 1 week | +13.79% | ||
| Current month | +13.79% | ||
| 1 month | -4.07% | ||
| 3 months | +29.92% | ||
| 6 months | +25.00% | ||
| Current year | +2.48% |
| 1 week | 71 |  | 85 |
| 1 month | 70 | | 90 |
| Current year | 55.27 | | 95 |
| 1 year | 55.27 | | 95 |
| 3 years | 35.4 | | 199 |
| 5 years | 35.4 | | 449 |
| 10 years | 35.4 | | 472 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 51 | 13/04/2021 |
David J. Ellam
DFI | Director of Finance/CFO | - | 18/11/2024 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 01/08/2007 |
| Director | Title | Age | Since |
|---|---|---|---|
Sarah Howell
BRD | Director/Board Member | 51 | 13/04/2021 |
Mohammad Fazeli
BRD | Director/Board Member | 61 | 01/09/2017 |
Andrew Richards
CHM | Chairman | 66 | 13/04/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 20/5/26 | Free | Chief Executive Officer | 160,000 | 0.4238% | ||
| 20/5/26 | Free | Executive/Senior Manager | 95,000 | 0.2516% | ||
| 20/5/26 | Free | Chief Financial Officer | 105,000 | 0.2781% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +13.79% | +13.79% | -56.58% | 49.86M | |
| -6.60% | -8.56% | +49.38% | +63.51% | 65B | |
| -4.09% | -0.11% | +2.22% | +53.15% | 51.19B | |
| +0.03% | +5.56% | +9.10% | +69.05% | 51.2B | |
| -1.53% | +2.70% | +30.48% | +34.12% | 43.93B | |
| -1.34% | +4.12% | +16.64% | +115.13% | 41.96B | |
| -5.97% | -6.22% | +228.95% | +454.22% | 38.14B | |
| +6.53% | +8.02% | +16.40% | +53.41% | 33.24B | |
| -0.90% | -10.49% | +37.09% | -3.70% | 25.2B | |
| -2.76% | -9.54% | -16.58% | -9.19% | 22.03B | |
| Average | -1.66% | -0.12% | +38.75% | +77.31% | 37.2B | |
| Weighted average by Cap. | -2.30% | -1.20% | +42.14% | +95.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 300K 400K 356K 330K 566K 37.98M 575K 3.96M 1.55M 19.82M 1.5M 1.47M 63.19M | 205K 273K 243K 225K 387K 25.96M 393K 2.71M 1.06M 13.54M 1.03M 1M 43.18M |
| Net income | - | - |
| Net Debt | -5.57M -7.43M -6.6M -6.12M -10.51M -705M -10.67M -73.55M -28.84M -368M -27.87M -27.28M -1.17B | -249K -332K -295K -273K -470K -31.5M -477K -3.29M -1.29M -16.44M -1.25M -1.22M -52.41M |
Employees
33
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/10/26 | GBX 82.50 | 0.00% | 83,875 |
| 15/10/26 | GBX 82.50 | +3.12% | 48,629 |
| 14/10/26 | GBX 80.00 | +6.67% | 19,113 |
| 13/10/26 | GBX 75.00 | 0.00% | 11,505 |
| 12/10/26 | GBX 75.00 | +3.45% | 58,831 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.8250GBP
Average target price
2.505GBP
Spread / Average Target
+203.64%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AREC Stock
Select your edition
All financial news and data tailored to specific country editions
